Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Total Current Liabilities: 2017-2025

Historic Total Current Liabilities for Crinetics Pharmaceuticals (CRNX) over the last 8 years, with Sep 2025 value amounting to $74.2 million.

  • Crinetics Pharmaceuticals' Total Current Liabilities rose 38.45% to $74.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $74.2 million, marking a year-over-year increase of 38.45%. This contributed to the annual value of $59.7 million for FY2024, which is 35.82% up from last year.
  • Latest data reveals that Crinetics Pharmaceuticals reported Total Current Liabilities of $74.2 million as of Q3 2025, which was up 8.42% from $68.4 million recorded in Q2 2025.
  • Crinetics Pharmaceuticals' 5-year Total Current Liabilities high stood at $74.2 million for Q3 2025, and its period low was $10.3 million during Q1 2021.
  • In the last 3 years, Crinetics Pharmaceuticals' Total Current Liabilities had a median value of $53.6 million in 2024 and averaged $51.1 million.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first dropped by 4.61% in 2021, then skyrocketed by 119.10% in 2022.
  • Crinetics Pharmaceuticals' Total Current Liabilities (Quarterly) stood at $16.0 million in 2021, then surged by 73.32% to $27.7 million in 2022, then skyrocketed by 58.50% to $43.9 million in 2023, then surged by 35.82% to $59.7 million in 2024, then surged by 38.45% to $74.2 million in 2025.
  • Its last three reported values are $74.2 million in Q3 2025, $68.4 million for Q2 2025, and $57.3 million during Q1 2025.